Latest Pharma Insights
Two For Two: GSK Gains US FDA Approval For Nuvalent Asset In NSCLC
GSK's Nelkarmi wins accelerated US approval for previously treated anaplastic lymphoma kinase-positive lung cancer, the second drug from its $10.6bn Nuvalent buyout to reach the market.
Scrip - November 18, 2026
GSK's Nelkarmi wins accelerated US approval for previously treated anaplastic lymphoma kinase-positive lung cancer, the second drug from its $10.6bn Nuvalent buyout to reach the market.
Scrip - November 18, 2026
Hone Health Raises $228M In Equity And Growth Funding, Backed By General Catalyst, Celeb Investors
Hone Health telehealth and longevity platform announced it raised $228m; $28m in equity in a Series A extension round and $200m in growth financing from General Catalyst’s CVF. The company has drawn multiple celebrity backers including Gwyneth Paltrow and “Jay-Z.”
Medtech Insight - November 18, 2026
Hone Health telehealth and longevity platform announced it raised $228m; $28m in equity in a Series A extension round and $200m in growth financing from General Catalyst’s CVF. The company has drawn multiple celebrity backers including Gwyneth Paltrow and “Jay-Z.”
Medtech Insight - November 18, 2026
Compounding Is No Substitute For Generic Competition On GLP-1s
The FDA has welcomed the advent of generic competition on GLP-1s as a long-term solution to high costs and is treating timely approval of obesity generics as an urgent public health priority. Meanwhile, GLP-1 compounding should not be used to address affordability, CDER Director Mike Davis said.
Generics Bulletin - November 18, 2026
The FDA has welcomed the advent of generic competition on GLP-1s as a long-term solution to high costs and is treating timely approval of obesity generics as an urgent public health priority. Meanwhile, GLP-1 compounding should not be used to address affordability, CDER Director Mike Davis said.
Generics Bulletin - November 18, 2026
Apotex And Glenmark Face Off In US Over Axitinib
Two rivals to Pfizer’s Inlyta (axitinib) have been launched in the US, with Apotex introducing a generic version of the kidney cancer treatment and Glenmark launching an authorized generic.
Generics Bulletin - November 18, 2026
Two rivals to Pfizer’s Inlyta (axitinib) have been launched in the US, with Apotex introducing a generic version of the kidney cancer treatment and Glenmark launching an authorized generic.
Generics Bulletin - November 18, 2026
Fixing The IRA For Biosimilars: How A Key Legislative Bill Could Rewrite US Price Negotiation
Julie Reed, executive director of the US Biosimilars Forum, explains how the Biosimilars Access and Affordability Act could help to clarify when Medicare price negotiation should be delayed for a brand biologic that has biosimilar competition on the horizon.
Generics Bulletin - November 18, 2026
Julie Reed, executive director of the US Biosimilars Forum, explains how the Biosimilars Access and Affordability Act could help to clarify when Medicare price negotiation should be delayed for a brand biologic that has biosimilar competition on the horizon.
Generics Bulletin - November 18, 2026
We Are Not Alone: The Frontier Labs Have Arrived In Drug Development
Anthropic and OpenAI are moving from selling AI tools to owning drug development workflows and assets. In 2027, techbio faces a squeeze and pharma may buy AI platforms, but it will be speed, not patent-cliff panic, driving deals.
In Vivo - November 18, 2026
Anthropic and OpenAI are moving from selling AI tools to owning drug development workflows and assets. In 2027, techbio faces a squeeze and pharma may buy AI platforms, but it will be speed, not patent-cliff panic, driving deals.
In Vivo - November 18, 2026
Wearable Data Glut Meets Proof And Payment Gaps, Milken Panelists Say
Patients are awash in wearable data, but panelists at the Milken Institute Future of Health Summit said turning it into better outcomes depends on payment models that reward AI-enabled care, validated metrics and clinicians willing to collaborate.
Medtech Insight - November 18, 2026
Patients are awash in wearable data, but panelists at the Milken Institute Future of Health Summit said turning it into better outcomes depends on payment models that reward AI-enabled care, validated metrics and clinicians willing to collaborate.
Medtech Insight - November 18, 2026
China Basic Medical Insurance Covers CAR-T For First Time
China has included a CAR-T therapy for the first time in its revised national drug reimbursement list, along with a siRNA drug, while a gene therapy was added to commercial insurance coverage.
Pink Sheet - November 18, 2026
China has included a CAR-T therapy for the first time in its revised national drug reimbursement list, along with a siRNA drug, while a gene therapy was added to commercial insurance coverage.
Pink Sheet - November 18, 2026
White House Withdraws Overton’s FDA Commissioner Bid Hours Before Senate Vote
The White House pulled Heidi Overton’s FDA nomination hours before a Senate vote. Cassidy says she had the votes; Democrats will likely vet the next pick.
HBW Insight - November 18, 2026
The White House pulled Heidi Overton’s FDA nomination hours before a Senate vote. Cassidy says she had the votes; Democrats will likely vet the next pick.
HBW Insight - November 18, 2026
Proposed US Rule May Boost Supplement Industry Chances In ‘Race To Market’ For New Ingredients
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
Harry’s Marketer Questions NARB Appeals Process Amid FTC Referral
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Two For Two: GSK Gains US FDA Approval For Nuvalent Asset In NSCLC
GSK's Nelkarmi wins accelerated US approval for previously treated anaplastic lymphoma kinase-positive lung cancer, the second drug from its $10.6bn Nuvalent buyout to reach the market.
Scrip - November 18, 2026
GSK's Nelkarmi wins accelerated US approval for previously treated anaplastic lymphoma kinase-positive lung cancer, the second drug from its $10.6bn Nuvalent buyout to reach the market.
Scrip - November 18, 2026
China Basic Medical Insurance Covers CAR-T For First Time
China has included a CAR-T therapy for the first time in its revised national drug reimbursement list, along with a siRNA drug, while a gene therapy was added to commercial insurance coverage.
Pink Sheet - November 18, 2026
China has included a CAR-T therapy for the first time in its revised national drug reimbursement list, along with a siRNA drug, while a gene therapy was added to commercial insurance coverage.
Pink Sheet - November 18, 2026
Hone Health Raises $228M In Equity And Growth Funding, Backed By General Catalyst, Celeb Investors
Hone Health telehealth and longevity platform announced it raised $228m; $28m in equity in a Series A extension round and $200m in growth financing from General Catalyst’s CVF. The company has drawn multiple celebrity backers including Gwyneth Paltrow and “Jay-Z.”
Medtech Insight - November 18, 2026
Hone Health telehealth and longevity platform announced it raised $228m; $28m in equity in a Series A extension round and $200m in growth financing from General Catalyst’s CVF. The company has drawn multiple celebrity backers including Gwyneth Paltrow and “Jay-Z.”
Medtech Insight - November 18, 2026
Wearable Data Glut Meets Proof And Payment Gaps, Milken Panelists Say
Patients are awash in wearable data, but panelists at the Milken Institute Future of Health Summit said turning it into better outcomes depends on payment models that reward AI-enabled care, validated metrics and clinicians willing to collaborate.
Medtech Insight - November 18, 2026
Patients are awash in wearable data, but panelists at the Milken Institute Future of Health Summit said turning it into better outcomes depends on payment models that reward AI-enabled care, validated metrics and clinicians willing to collaborate.
Medtech Insight - November 18, 2026
White House Withdraws Overton’s FDA Commissioner Bid Hours Before Senate Vote
The White House pulled Heidi Overton’s FDA nomination hours before a Senate vote. Cassidy says she had the votes; Democrats will likely vet the next pick.
HBW Insight - November 18, 2026
The White House pulled Heidi Overton’s FDA nomination hours before a Senate vote. Cassidy says she had the votes; Democrats will likely vet the next pick.
HBW Insight - November 18, 2026
Proposed US Rule May Boost Supplement Industry Chances In ‘Race To Market’ For New Ingredients
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
Harry’s Marketer Questions NARB Appeals Process Amid FTC Referral
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Compounding Is No Substitute For Generic Competition On GLP-1s
The FDA has welcomed the advent of generic competition on GLP-1s as a long-term solution to high costs and is treating timely approval of obesity generics as an urgent public health priority. Meanwhile, GLP-1 compounding should not be used to address affordability, CDER Director Mike Davis said.
Generics Bulletin - November 18, 2026
The FDA has welcomed the advent of generic competition on GLP-1s as a long-term solution to high costs and is treating timely approval of obesity generics as an urgent public health priority. Meanwhile, GLP-1 compounding should not be used to address affordability, CDER Director Mike Davis said.
Generics Bulletin - November 18, 2026
Apotex And Glenmark Face Off In US Over Axitinib
Two rivals to Pfizer’s Inlyta (axitinib) have been launched in the US, with Apotex introducing a generic version of the kidney cancer treatment and Glenmark launching an authorized generic.
Generics Bulletin - November 18, 2026
Two rivals to Pfizer’s Inlyta (axitinib) have been launched in the US, with Apotex introducing a generic version of the kidney cancer treatment and Glenmark launching an authorized generic.
Generics Bulletin - November 18, 2026
Fixing The IRA For Biosimilars: How A Key Legislative Bill Could Rewrite US Price Negotiation
Julie Reed, executive director of the US Biosimilars Forum, explains how the Biosimilars Access and Affordability Act could help to clarify when Medicare price negotiation should be delayed for a brand biologic that has biosimilar competition on the horizon.
Generics Bulletin - November 18, 2026
Julie Reed, executive director of the US Biosimilars Forum, explains how the Biosimilars Access and Affordability Act could help to clarify when Medicare price negotiation should be delayed for a brand biologic that has biosimilar competition on the horizon.
Generics Bulletin - November 18, 2026
We Are Not Alone: The Frontier Labs Have Arrived In Drug Development
Anthropic and OpenAI are moving from selling AI tools to owning drug development workflows and assets. In 2027, techbio faces a squeeze and pharma may buy AI platforms, but it will be speed, not patent-cliff panic, driving deals.
In Vivo - November 18, 2026
Anthropic and OpenAI are moving from selling AI tools to owning drug development workflows and assets. In 2027, techbio faces a squeeze and pharma may buy AI platforms, but it will be speed, not patent-cliff panic, driving deals.
In Vivo - November 18, 2026




